Search

Your search keyword '"Dufour J.-F."' showing total 356 results

Search Constraints

Start Over You searched for: Author "Dufour J.-F." Remove constraint Author: "Dufour J.-F."
356 results on '"Dufour J.-F."'

Search Results

51. Intermediate hepatocellular carcinoma: current treatments and future perspectives

52. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

53. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

54. Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy

56. Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis

57. Trends in Hepatitis C-related mortality in Switzerland

58. Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies

61. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

62. Survival after liver transplantation

65. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, with or without Ribavirin, in Adults Treated with the Regimen Approved in Australia, Canada, New Zealand, and Switzerland

66. Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir without Ribavirin in Patients with HCV Genotype 1b with or without Compensated Cirrhosis: Pooled Analysis across 5 Clinical Trials

68. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin

75. P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials

79. Impact of common risk factors of fibrosis progression in chronic hepatitis C

81. P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES

82. P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR

83. P196 INVESTIGATION OF HEPATITIS C VIRUS ADAPTATION TO HOST GENETIC POLYMORPHISMS

84. P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALS

85. P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS

86. P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS

87. P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS

92. The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection

94. 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

95. 1412 COMPARATIVE GENETIC ANALYSES POINT TO HCP5 AS SUSCEPTIBILITY LOCUS FOR HCV-ASSOCIATED HEPATOCELLULAR CARCINOMA

96. 504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS

98. 1364 THE HOMA INDEX IS A USEFUL TOOL FOR RISK STRATIFICATION OF ADVANCED FIBROTIC DISEASE IN A LARGE COHORT OF EUROPEAN NAFLD PATIENTS

99. Signaling Pathways in Liver Diseases

100. 932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS

Catalog

Books, media, physical & digital resources